Quick Answer
Krystal Biotech, Inc. reported Total Assets of $1.33 billion for the year ending 2025.
- Krystal Biotech, Inc. showed an increase of +26.3% in Total Assets from 2024 to 2025.
- This data is from Krystal Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $52.67 million | Q4 2017: $50.11 million | Q1 2018: $47.85 million | Q2 2018: $46.03 million | Q3 2018: $54.45 million | Q1 2019: $115.70 million | Q2 2019: $205.16 million | Q3 2019: $214.23 million | Q1 2020: $205.13 million | Q2 2020: $318.15 million | Q3 2020: $311.45 million | Q1 2021: $443.02 million | Q2 2021: $443.56 million | Q3 2021: $451.10 million | Q1 2022: $616.87 million | Q2 2022: $601.32 million | Q3 2022: $576.38 million | Q1 2023: $531.85 million | Q2 2023: $684.03 million | Q3 2023: $790.35 million | Q1 2024: $853.30 million | Q2 2024: $917.66 million | Q3 2024: $982.32 million | Q1 2025: $1.07 billion | Q2 2025: $1.14 billion | Q3 2025: $1.24 billion.
- Over the full 10 years of available data (2016 to 2025), Krystal Biotech, Inc.'s Total Assets has grown by 61,027.1%.
- Historical annual values: Fiscal year 2025: $1.33 billion | Fiscal year 2024: $1.06 billion | Fiscal year 2023: $818.36 million | Fiscal year 2022: $558.45 million | Fiscal year 2021: $626.30 million | Fiscal year 2020: $310.84 million | Fiscal year 2019: $209.02 million | Fiscal year 2018: $116.12 million | Fiscal year 2017: $50.11 million | Fiscal year 2016: $2.18 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: